Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent and Trademark office (USPTO) has issued a Patent no. 7910543 to NephRx for its novel peptide, NX002.
Subscribe to our email newsletter
The patent entitled: ‘Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors,’ protects NX002 and related compounds.
Currently, NX002 is in preclinical development for the treatment of mucositis and has showed efficacy in a study evaluated well-validated animal models of oral mucositis.
NephRx president and CEO James Koziarz said issuance of this most recent patent further confirms the promising utility of NX002 as a potential treatment for oral mucositis.
"We look forward to advancing the detailed NX002 toxicity studies needed to initiate the mucositis clinical program for NX002," Koziarz said.